KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Intangibles: 2022-2024

Historic Intangibles for Halozyme Therapeutics (HALO) over the last 3 years, with Dec 2024 value amounting to $401.8 million.

  • Halozyme Therapeutics' Intangibles fell 16.93% to $348.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.5 million, marking a year-over-year decrease of 16.93%. This contributed to the annual value of $401.8 million for FY2024, which is 15.02% down from last year.
  • Halozyme Therapeutics' Intangibles amounted to $401.8 million in FY2024, which was down 15.02% from $472.9 million recorded in FY2023.
  • Halozyme Therapeutics' Intangibles' 5-year high stood at $546.7 million during FY2022, with a 5-year trough of $401.8 million in FY2024.
  • For the 3-year period, Halozyme Therapeutics' Intangibles averaged around $473.8 million, with its median value being $472.9 million (2023).
  • Data for Halozyme Therapeutics' Intangibles shows a maximum YoY fell of 15.02% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Halozyme Therapeutics' Intangibles stood at $546.7 million in 2022, then dropped by 13.50% to $472.9 million in 2023, then fell by 15.02% to $401.8 million in 2024.